scholarly journals Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Verónica López ◽  
Jesús Pino ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Pathologic Alteration ◽  
Holistic Vision

Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed, the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and several suggestions for future perspectives and potential clinical implications.

scholarly journals DDAH gene and cardiovascular risk

2005 ◽  
Vol 10 (1_suppl) ◽  
pp. S45-S48 ◽  
Author(s):  
Veli-Pekka Valkonen ◽  
Tomi-Pekka Tuomainen ◽  
Reijo Laaksonen
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
High Plasma ◽  
No Synthase ◽  
Clinical Role ◽  
Plasma Adma ◽  
Increased Risk ◽  
Major Route ◽  
Increased Susceptibility

The crucial role of nitric oxide (NO) for normal endothelial function is well known. In many conditions associated with increased risk of cardiovascular diseases such as hypercholesterolemia, hypertension, abdominal obesity, diabetes and smok ing, NO biosynthesis is dysregulated, leading to endothelial dysfunction. The grow ing evidence from animal and human studies indicates that endogenous inhibitors of endothelial NO synthase such as asymmetric dimethylarginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA) are associated with the endothelial dysfunc tion and potentially regulate NO synthase. The major route of elimination of ADMA is metabolism by the enzymes dimethylarginine dimethylaminohydrolase-1 and -2 (DDAH). In our recent study 16 men with either low or high plasma ADMA concen trations were screened to identify DDAH polymorphisms that could potentially be associated with increased susceptibility to cardiovascular diseases. In that study a novel functional mutation of DDAH-1 was identified; the mutation carriers had a significantly elevated risk for cardiovascular disease and a tendency to develop hypertension. These results confirmed the clinical role of DDAH enzymes in ADMA metabolism. Furthermore, it is possible that more common variants of DDAH genes contribute more widely to increased cardiovascular risk.

scholarly journals Adipokines, Metabolic Syndrome and Rheumatic Diseases

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Vanessa Abella ◽  
Morena Scotece ◽  
Javier Conde ◽  
Verónica López ◽  
Verónica Lazzaro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Cardiovascular Risk ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Vascular Function ◽  
Central Obesity ◽  
Cvd Risk ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Cardiometabolic Disorders

The metabolic syndrome (MetS) is a cluster of cardiometabolic disorders that result from the increasing prevalence of obesity. The major components of MetS include insulin resistance, central obesity, dyslipidemia, and hypertension. MetS identifies the central obesity with increased risk for cardiovascular diseases (CVDs) and type-2 diabetes mellitus (T2DM). Patients with rheumatic diseases, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis, have increased prevalence of CVDs. Moreover, CVD risk is increased when obesity is present in these patients. However, traditional cardiovascular risk factors do not completely explain the enhanced cardiovascular risk in this population. Thus, MetS and the altered secretion patterns of proinflammatory adipokines present in obesity could be the link between CVDs and rheumatic diseases. Furthermore, adipokines have been linked to the pathogenesis of MetS and its comorbidities through their effects on vascular function and inflammation. In the present paper, we review recent evidence of the role played by adipokines in the modulation of MetS in the general population, and in patients with rheumatic diseases.

Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases

2020 ◽  
Vol 18 (6) ◽  
pp. 533-537
Author(s):  
Antonis S. Manolis ◽  
Athanasios G. Tzioufas
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Thematic Issue ◽  
Preventive Strategies ◽  
Systemic Lupus ◽  
Autoimmune Rheumatic Diseases ◽  
Disease Modifying

In Part 1 of this Thematic Issue entitled “Systemic Autoimmune Rheumatic Diseases and Cardiology”, a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of spondyloarthritides, rheumatoid arthritis, Sjogren’s syndrome and vasculitides, as well as relevant cardiovascular issues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided their recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts discuss the enhanced cardiovascular risk conferred by additional autoimmune rheumatic diseases (ARDs), including systemic lupus erythematosus, the antiphospholipid syndrome, psoriasis and psoriatic arthritis and juvenile idiopathic arthritis. These, and the previous articles, place inflammation as the key common link to explain the enhanced risk of cardiovascular complications in patients with ARDs. It follows that treatment should probably target inflammation. From all these contemporary reviews, the conclusion that is derived further supports the notion of the emerging field of Cardio- Rheumatology where physicians and experts from these two disciplines collaborate in risk stratification and optimization of preventive strategies and drug therapies in patients with ARDs.

scholarly journals Complement Activation on Endothelial Cell-Derived Microparticles—A Key Determinant for Cardiovascular Risk in Patients with Systemic Lupus Erythematosus?

Medicina ◽  
2020 ◽  
Vol 56 (10) ◽  
pp. 533
Author(s):  
Naomi Martin ◽  
Xiaodie Tu ◽  
Alicia J. Egan ◽  
Cordula Stover
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cardiovascular Risk ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Chronic Inflammatory Disease ◽  
Systemic Autoimmune Disease ◽  
Systemic Lupus ◽  
Additional Risk ◽  
Increased Risk ◽  
Circulating Microparticles

Systemic lupus erythematosus is a classical systemic autoimmune disease that overactivates complement and can affect all organs. Early diagnosis and effective management are important in this immune-complex-mediated chronic inflammatory disease, which has a strong component of vasculitis and carries an increased risk of thrombosis, even in the absence of antiphospholipid antibodies. Development of lupus nephritis can be life limiting but is managed with dialysis and renal transplantation. Therefore, data have become available that cardiovascular risk poses a serious feature of systemic lupus erythematosus that requires monitoring and prospective treatment. Cell-derived microparticles circulate in plasma and thereby intersect the humoral and cellular component of inflammation. They are involved in disease pathophysiology, particularly thrombosis, and represent a known cardiovascular risk. This viewpoint argues that a focus on characteristics of circulating microparticles measured in patients with systemic lupus erythematosus may help to classify certain ethnic groups who are especially at additional risk of experiencing cardiovascular complications.

scholarly journals DDAH gene and cardiovascular risk

2005 ◽  
Vol 10 (2_suppl) ◽  
pp. S45-S48 ◽  
Author(s):  
Veli-Pekka Valkonen ◽  
Tomi-Pekka Tuomainen ◽  
Reijo Laaksonen
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Endothelial Dysfunction ◽  
High Plasma ◽  
No Synthase ◽  
Clinical Role ◽  
Plasma Adma ◽  
Increased Risk ◽  
Major Route

The crucial role of nitric oxide (NO) for normal endothelial function is well known. In many conditions associated with increased risk of cardiovascular diseases such as hypercholesterolemia, hypertension, abdominal obesity, diabetes and smoking, NO biosynthesis is dysregulated, leading to endothelial dysfunction. The growing evidence from animal and human studies indicates that endogenous inhibitors of endothelial NO synthase such as asymmetric dimethylarginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA) are associated with the endothelial dysfunction and potentially regulate NO synthase. The major route of elimination of ADMA is metabolism by the enzymes dimethylarginine dimethylaminohydrolase-1 and -2 (DDAH). In our recent study 16 men with either low or high plasma ADMA concentrations were screened to identify DDAH polymorphisms that could potentially be associated with increased susceptibility to cardiovascular diseases. In that study a novel functional mutation of DDAH-1 was identified; the mutation carriers had a significantly elevated risk for cardiovascular disease and a tendency to develop hypertension. These results confirmed the clinical role of DDAH enzymes in ADMA metabolism. Furthermore, it is possible that more common variants of DDAH genes contribute more widely to increased cardiovascular risk.

The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases

Rheumatology ◽  
2020 ◽  
Vol 59 (12) ◽  
pp. 3593-3602
Author(s):  
Serena Fasano ◽  
Daniela Iacono ◽  
Antonella Riccardi ◽  
Francesco Ciccia ◽  
Gabriele Valentini
Keyword(s):  
Primary Prevention ◽  
General Population ◽  
Rheumatic Diseases ◽  
Cardiovascular Prevention ◽  
Cardiovascular Complications ◽  
Increased Risk ◽  
High Risk Populations ◽  
Systemic Rheumatic Diseases ◽  
General Aspects

Abstract Aspirin is the most commonly used medication worldwide. Beside its well-known anti-inflammatory effects, a role has emerged in the prevention of cardiovascular events. However, a significant benefit has been demonstrated in secondary cardiovascular prevention only, while there is limited evidence supporting a role in primary prevention. This discrepancy might depend on the that so far, the high-risk populations that will achieve the greatest benefits yet experiencing minimal harmful side effects have not been identified. Patients with autoimmune systemic rheumatic diseases have an increased risk of cardiovascular complications compared with the general population, which makes aspirin of potential value in these subjects. Moving from general aspects of aspirin pharmacology and specific issues in general population, the aim of this study is to review the evidence about the role of low-dose aspirin in primary cardiovascular prevention in autoimmune systemic rheumatic diseases.

scholarly journals Cardiovascular complications in patients with rheumatic diseases.

2018 ◽  
Vol 96 (5) ◽  
pp. 411-418
Author(s):  
A. V. Arshinov ◽  
V. I. Emanuilov ◽  
I. G. Maslova
Keyword(s):  
Risk Factors ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Systemic Lupus ◽  
Increased Risk ◽  
Male Sex ◽  
Traditional Risk Factors ◽  
Vascular Accidents ◽  
Large Vessels

In the recent years, there are more and more reports stating an increased risk of atherosclerosis and cardiovascular complications in patients with rheumatic diseases. It should be noted that the development of atherosclerosis in this category of patients occurs much earlier than in the general population. Indeed, many rheumatic diseases are associated with an increased risk of developing of cardiovascular diseases and death from vascular accidents, including RA, systemic lupus erythematosus, ankylosing spondylitis, gout, psoriatic arthritis, vasculitis of the middle and large vessels. There are reports of an increased risk of cardiovascular disease in patients with systemic scleroderma. It is significant that rheumatic diseases and coronary heart disease combine common pathophysiological mechanisms - systemic and chronic inflammation. At the same time, traditional risk factors such as hypertension, old age, smoking, hypercholesterolemia, obesity and male sex can not fully explain the mechanism of accelerated development of atherosclerosis in patients with rheumatic diseases. The presence of specific risk factors, such as the duration of the course of treatment, glucocorticosteroids administration, the presence of an increased concentration of inflammatory mediators and autoimmune mechanisms create conditions for the acceleration of atherosclerosis in this group of patients. Coordination of efforts of rheumatologists and cardiologists in studying the mechanisms of accelerated development of atherosclerosis in patients with rheumatic diseases will allow to develop adequate methods for timely diagnosis and prevention of cardiovascular complications in patients with this widespread pathology.

Main approaches to prevention of health disorders in workers in contact with physical factors

2020 ◽  
Vol 60 (11) ◽  
pp. 827-829
Author(s):  
Andrey V. Melentyev
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Machine Building ◽  
Working Environment ◽  
Physical Factors ◽  
Noise And Vibration ◽  
Industrial Enterprises ◽  
Increased Risk ◽  
Health Disorders ◽  
Building Enterprises

Introduction. One of the leading causes of occupational health loss, especially in mining and machine-building enterprises, is the combined impact of industrial noise and vibration. The wide prevalence of cardiovascular diseases is one of the most important medical and social problems, due to persistent disability and high mortality, bringing prevention of health disorders to the first place as the basis for preserving labor longevity. The aim of study is to identify the main approaches aimed at preventing health problems in workers who come into contact with vibration and noise at mining and machine-building enterprises. Materials and methods. A survey and survey of 296 industrial workers was conducted. Group 1 (160 people) included men who were exposed to noise and vibration factors above the maximum permissible levels, group 2 consisted of 136 men who did not have direct contact with noise and vibration generating equipment. When conducting an in-depth laboratory and instrumental examination in a hospital setting, all workers additionally calculated the level of cardiovascular risk on the SCORE scale. Statistical analysis was performed using the software package "Statistica 6.0". Results. It is determined that the priority adverse factors of the working environment in production are noise and vibration. It has been shown that individuals who come into contact with these factors are more likely to detect violations of lipid metabolism and endothelial function, have a higher average heart rate and systolic blood pressure, and have an increased risk of developing cardiovascular diseases. Conclusions. Taking into account the obtained results of the proposed diagnostic approaches aimed at the prevention of health disorders among workers of industrial enterprises. If employees are found to have an increased cardiovascular risk, it is necessary to conduct a more in-depth examination and timely medical and preventive measures.

scholarly journals The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Peter Cox ◽  
Sonal Gupta ◽  
Sizheng Steven Zhao ◽  
David M. Hughes
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Random Effect ◽  
Small Sample ◽  
Future Research ◽  
Increased Risk

AbstractThe aims of this systematic review and meta-analysis were to describe prevalence of cardiovascular disease in gout, compare these results with non-gout controls and consider whether there were differences according to geography. PubMed, Scopus and Web of Science were systematically searched for studies reporting prevalence of any cardiovascular disease in a gout population. Studies with non-representative sampling, where a cohort had been used in another study, small sample size (< 100) and where gout could not be distinguished from other rheumatic conditions were excluded, as were reviews, editorials and comments. Where possible meta-analysis was performed using random-effect models. Twenty-six studies comprising 949,773 gout patients were included in the review. Pooled prevalence estimates were calculated for five cardiovascular diseases: myocardial infarction (2.8%; 95% confidence interval (CI)s 1.6, 5.0), heart failure (8.7%; 95% CI 2.9, 23.8), venous thromboembolism (2.1%; 95% CI 1.2, 3.4), cerebrovascular accident (4.3%; 95% CI 1.8, 9.7) and hypertension (63.9%; 95% CI 24.5, 90.6). Sixteen studies reported comparisons with non-gout controls, illustrating an increased risk in the gout group across all cardiovascular diseases. There were no identifiable reliable patterns when analysing the results by country. Cardiovascular diseases are more prevalent in patients with gout and should prompt vigilance from clinicians to the need to assess and stratify cardiovascular risk. Future research is needed to investigate the link between gout, hyperuricaemia and increased cardiovascular risk and also to establish a more thorough picture of prevalence for less common cardiovascular diseases.

scholarly journals Osteopontin in Cardiovascular Diseases

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1047
Author(s):  
Kohsuke Shirakawa ◽  
Motoaki Sano
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Therapeutic Target ◽  
Gene Mutations ◽  
Major Adverse Cardiovascular Event ◽  
Matricellular Protein ◽  
Pathological State ◽  
Adverse Cardiovascular Event ◽  
Anti Inflammatory

Unprecedented advances in secondary prevention have greatly improved the prognosis of cardiovascular diseases (CVDs); however, CVDs remain a leading cause of death globally. These findings suggest the need to reconsider cardiovascular risk and optimal medical therapy. Numerous studies have shown that inflammation, pro-thrombotic factors, and gene mutations are focused not only on cardiovascular residual risk but also as the next therapeutic target for CVDs. Furthermore, recent clinical trials, such as the Canakinumab Anti-inflammatory Thrombosis Outcomes Study trial, showed the possibility of anti-inflammatory therapy for patients with CVDs. Osteopontin (OPN) is a matricellular protein that mediates diverse biological functions and is involved in a number of pathological states in CVDs. OPN has a two-faced phenotype that is dependent on the pathological state. Acute increases in OPN have protective roles, including wound healing, neovascularization, and amelioration of vascular calcification. By contrast, chronic increases in OPN predict poor prognosis of a major adverse cardiovascular event independent of conventional cardiovascular risk factors. Thus, OPN can be a therapeutic target for CVDs but is not clinically available. In this review, we discuss the role of OPN in the development of CVDs and its potential as a therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document